Pepose Vision Institute

With $16.5M in New Funding, Fort Worth’s Nacuity Aims to Treat ‘Serious Blinding and Chronic Diseases’

by | Jun 15, 2022
Nacuity Pharmaceuticals focuses on ocular diseases caused by oxidative stress in the retina, including age-related macular degeneration, glaucoma, and diabetic retinopathy. The $16.5M funding, led by the Foundation Fighting Blindness, will help advance two Nacuity clinical trials. “This funding will help further our mission to develop a breakthrough treatment for retinitis pigmentosa and other serious blinding and chronic diseases," said Nacuity Chairman, CEO, and Co-founder Halden Conner.
MORE
Protecting your privacy. We have strengthened our Privacy Policy to better protect you. This Policy includes our use of cookies to give you the best online experience and provide functionality essential to our services. By clicking ‘I Accept’ or by continuing to use our website, you are consenting to our Privacy Policy.